628 related articles for article (PubMed ID: 31603846)
1. [Neuromyelitis optica].
Ferrán C; Pedemonte V; Turcatti E; González G
Medicina (B Aires); 2019; 79 Suppl 3():60-65. PubMed ID: 31603846
[TBL] [Abstract][Full Text] [Related]
2. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
3. What You Need to Know About AQP4, MOG, and NMOSD.
Prasad S; Chen J
Semin Neurol; 2019 Dec; 39(6):718-731. PubMed ID: 31847043
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
6. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
[TBL] [Abstract][Full Text] [Related]
7. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.
Sharma J; Bhatti MT; Danesh-Meyer HV
Clin Exp Ophthalmol; 2021 Mar; 49(2):186-202. PubMed ID: 33426799
[TBL] [Abstract][Full Text] [Related]
11. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
12. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].
Aktas O; Kümpfel T
Nervenarzt; 2021 Apr; 92(4):307-316. PubMed ID: 33728474
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
14. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
[TBL] [Abstract][Full Text] [Related]
15. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic criteria and differential diagnosis of neuromyelitis optica].
Nakashima I
Nihon Rinsho; 2014 Nov; 72(11):1964-9. PubMed ID: 25518378
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica spectrum disorder (NMOSD): A new concept.
de Sèze J; Kremer L; Collongues N
Rev Neurol (Paris); 2016; 172(4-5):256-62. PubMed ID: 27157418
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis Optica Spectrum Disorders.
Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K
Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging in neuromyelitis optica spectrum disorder.
Clarke L; Arnett S; Lilley K; Liao J; Bhuta S; Broadley SA
Clin Exp Immunol; 2021 Dec; 206(3):251-265. PubMed ID: 34080180
[TBL] [Abstract][Full Text] [Related]
20. [Clinical concept, etiology and pathology of neuromyelitis optica].
Kurosawa K; Fujihara K
Nihon Rinsho; 2014 Nov; 72(11):1897-902. PubMed ID: 25518368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
